Eli Lilly's new oral weight loss pill, orforglipron, shows promise in Phase 3 trials, offering a convenient alternative to ...

CEO Dave Ricks said Friday that the company will make its planned GLP-1 weight-loss pill in the U.S. amid President Donald ...

Shares of Novo Nordisk, the Danish pharmaceutical company behind weight-loss drugs Ozempic and Wegovy, plummeted this week.

Eli Lilly & Co. shares surged after its experimental pill helped patients shed weight and control blood sugar about as well ...

Eli Lilly stocks displayed a major rise after the announcement of a new oral weight-loss drug that has put pressure on its ...

Orforglipron, a new nonpeptide GLP-1 drug, may provide easier access for the treatment of Type 2 diabetes and obesity without ...

A DAILY weight loss pill that works like Ozempic has succeeded in a major clinical trial. Patients lost an average of a stone ...

Eli Lilly’s new obesity and diabetes pill has shown it can lower blood sugar and aid weight loss in a late-stage trial, ...

Diabetics given the pill called orforglipron lost 16 pounds, or 7.9% of their body weight, over a 40-week period.

Eli Lilly said its drugs showed no signs of live injury in the trial. This is welcome news for researchers after Pfizer ...

Weight loss drug Wegovy uses the same drug as Ozempic, called semaglutide, and has been licensed for use in the UK. Wegovy ...

Bloomberg journalists discuss today's biggest winners and losers in the stock market. Listen for analysis on the companies ...